866-997-4948(US-Canada Toll Free)

Streptococcal Pneumonia - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Dec 2016

Category :

Pharmaceutical

No. of Pages : 160 Pages

Streptococcal Pneumonia - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Streptococcal Pneumonia Pipeline Review, H2 2016, provides an overview of the Streptococcal Pneumonia (Infectious Disease) pipeline landscape.

Pneumococcal infections are caused by the Streptococcus pneumoniae (S. pneumoniae) bacterium. They can be mild or severe. Symptoms include fever, chills, sweat, aches and pains. Risk factors include serious health condition, such as HIV or diabetes that weakens their immune system, taking medication that weakens their immune system, such as chemotherapy and age. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Streptococcal Pneumonia Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Streptococcal Pneumonia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Streptococcal Pneumonia (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Streptococcal Pneumonia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 3, 6, 6, 2, 22, 10 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Preclinical and Discovery stages comprises 1, 1, 8 and 4 molecules, respectively.

Streptococcal Pneumonia (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Streptococcal Pneumonia (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Streptococcal Pneumonia (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Streptococcal Pneumonia (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Streptococcal Pneumonia (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Streptococcal Pneumonia (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Streptococcal Pneumonia (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Streptococcal Pneumonia (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Introduction 5
Streptococcal Pneumonia Overview 6
Therapeutics Development 7
Streptococcal Pneumonia - Therapeutics under Development by Companies 9
Streptococcal Pneumonia - Therapeutics under Investigation by Universities/Institutes 11
Streptococcal Pneumonia - Pipeline Products Glance 12
Streptococcal Pneumonia - Products under Development by Companies 16
Streptococcal Pneumonia - Products under Investigation by Universities/Institutes 19
Streptococcal Pneumonia - Companies Involved in Therapeutics Development 20
Streptococcal Pneumonia - Therapeutics Assessment 54
Drug Profiles 64
Streptococcal Pneumonia - Dormant Projects 136
Streptococcal Pneumonia - Discontinued Products 140
Streptococcal Pneumonia - Product Development Milestones 141
Appendix 152

List of Tables
Number of Products under Development for Streptococcal Pneumonia, H2 2016 14
Number of Products under Development for Streptococcal Pneumonia - Comparative Analysis, H2 2016 15
Number of Products under Development by Companies, H2 2016 16
Number of Products under Development by Companies, H2 2016 (Contd..1) 17
Number of Products under Investigation by Universities/Institutes, H2 2016 18
Comparative Analysis by Late Stage Development, H2 2016 19
Comparative Analysis by Clinical Stage Development, H2 2016 20
Comparative Analysis by Early Stage Development, H2 2016 21
Comparative Analysis by Unknown Stage Development, H2 2016 22
Products under Development by Companies, H2 2016 23
Products under Development by Companies, H2 2016 (Contd..1) 24
Products under Development by Companies, H2 2016 (Contd..2) 25
Products under Investigation by Universities/Institutes, H2 2016 26
Streptococcal Pneumonia - Pipeline by Abera Bioscience AB, H2 2016 27
Streptococcal Pneumonia - Pipeline by Actelion Ltd, H2 2016 28
Streptococcal Pneumonia - Pipeline by Affinivax Inc, H2 2016 29
Streptococcal Pneumonia - Pipeline by Allergan Plc, H2 2016 30
Streptococcal Pneumonia - Pipeline by Arsanis Inc, H2 2016 31
Streptococcal Pneumonia - Pipeline by AstraZeneca Plc, H2 2016 32
Streptococcal Pneumonia - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2016 33
Streptococcal Pneumonia - Pipeline by Biken Inc, H2 2016 34
Streptococcal Pneumonia - Pipeline by ContraFect Corp, H2 2016 35
Streptococcal Pneumonia - Pipeline by Crestone Inc, H2 2016 36
Streptococcal Pneumonia - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 37
Streptococcal Pneumonia - Pipeline by FluGen Inc, H2 2016 38
Streptococcal Pneumonia - Pipeline by GlaxoSmithKline Plc, H2 2016 39
Streptococcal Pneumonia - Pipeline by ImmunoBiology Ltd, H2 2016 40
Streptococcal Pneumonia - Pipeline by Indian Immunologicals Ltd, H2 2016 41
Streptococcal Pneumonia - Pipeline by Integrated BioTherapeutics Inc, H2 2016 42
Streptococcal Pneumonia - Pipeline by Lascco SA, H2 2016 43
Streptococcal Pneumonia - Pipeline by LegoChem Biosciences Inc, H2 2016 44
Streptococcal Pneumonia - Pipeline by Liquidia Technologies Inc, H2 2016 45
Streptococcal Pneumonia - Pipeline by Merck & Co Inc, H2 2016 46
Streptococcal Pneumonia - Pipeline by Mucosis BV, H2 2016 47
Streptococcal Pneumonia - Pipeline by Panacea Biotec Ltd, H2 2016 48
Streptococcal Pneumonia - Pipeline by Pfizer Inc, H2 2016 49
Streptococcal Pneumonia - Pipeline by Prometheon Pharma LLC, H2 2016 50
Streptococcal Pneumonia - Pipeline by Sanofi Pasteur SA, H2 2016 51
Streptococcal Pneumonia - Pipeline by Serum Institute of India Ltd, H2 2016 52
Streptococcal Pneumonia - Pipeline by Shionogi & Co Ltd, H2 2016 53
Streptococcal Pneumonia - Pipeline by SK Chemicals Co Ltd, H2 2016 54
Streptococcal Pneumonia - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016 55
Streptococcal Pneumonia - Pipeline by Valneva SE, H2 2016 56
Streptococcal Pneumonia - Pipeline by Vaxxilon AG, H2 2016 57
Streptococcal Pneumonia - Pipeline by Virometix AG, H2 2016 58
Streptococcal Pneumonia - Pipeline by Wellstat Vaccines LLC, H2 2016 59
Streptococcal Pneumonia - Pipeline by Wockhardt Ltd, H2 2016 60
Assessment by Monotherapy Products, H2 2016 61
Assessment by Combination Products, H2 2016 62
Number of Products by Stage and Target, H2 2016 64
Number of Products by Stage and Mechanism of Action, H2 2016 66
Number of Products by Stage and Route of Administration, H2 2016 68
Number of Products by Stage and Molecule Type, H2 2016 70
Streptococcal Pneumonia - Dormant Projects, H2 2016 143
Streptococcal Pneumonia - Dormant Projects (Contd..1), H2 2016 144
Streptococcal Pneumonia - Dormant Projects (Contd..2), H2 2016 145
Streptococcal Pneumonia - Dormant Projects (Contd..3), H2 2016 146
Streptococcal Pneumonia - Discontinued Products, H2 2016 147

List of Figures
Number of Products under Development for Streptococcal Pneumonia, H2 2016 14
Number of Products under Development for Streptococcal Pneumonia - Comparative Analysis, H2 2016 15
Number of Products under Development by Companies, H2 2016 16
Number of Products under Investigation by Universities/Institutes, H2 2016 18
Comparative Analysis by Late Stage Development, H2 2016 19
Comparative Analysis by Clinical Stage Development, H2 2016 20
Comparative Analysis by Early Stage Products, H2 2016 21
Assessment by Monotherapy Products, H2 2016 61
Number of Products by Top 10 Targets, H2 2016 63
Number of Products by Stage and Top 10 Targets, H2 2016 63
Number of Products by Top 10 Mechanism of Actions, H2 2016 65
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 65
Number of Products by Routes of Administration, H2 2016 67
Number of Products by Stage and Routes of Administration, H2 2016 67
Number of Products by Molecule Types, H2 2016 69
Number of Products by Stage and Top 10 Molecule Types, H2 2016 69

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *